Institute for Clinical and Economic Review Releases Draft Evidence Report on Therapies for Hemophilia A
August 27, 2020
August 27, 2020
BOSTON, Massachusetts, Aug. 27 -- The Institute for Clinical and Economic Review issued the following announcement on Aug. 26:
The Institute for Clinical and Economic Review (ICER) today released a Draft Evidence Report assessing the comparative clinical effectiveness and value of treatments for hemophilia A; this assessment includes valoctocogene roxaparvovec (Roctavian(TM), BioMarin Pharmaceutical) and emicizumab (Hemlibra(R), Genentech). ICER is proceeding with this assessment de . . .
The Institute for Clinical and Economic Review (ICER) today released a Draft Evidence Report assessing the comparative clinical effectiveness and value of treatments for hemophilia A; this assessment includes valoctocogene roxaparvovec (Roctavian(TM), BioMarin Pharmaceutical) and emicizumab (Hemlibra(R), Genentech). ICER is proceeding with this assessment de . . .